Selenium sulfide

CASRN 7446-34-6

  • IRIS Summary (PDF) (12 pp, 109 K)
  • Status: Selenium sulfide is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (12 pp, 109 K)
Not assessed under the IRIS Program.

Reference Concentration for Inhalation Exposure (RfC) (PDF) (12 pp, 109 K)
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (12 pp, 109 K) last updated: 03/01/1991

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Based on inadequate data from human studies and sufficient evidence in animals. When administered orally, selenium sulfide produced hepatocellular carcinomas in both sexes of F344 rats and female B6C3F1 mice and alveolar/bronchiolar carcinomas or adenomas in female B6C3F1 mice.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (12 pp, 109 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (12 pp, 109 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.